Immunotherapy By Cancer Type

Bladder Cancer

The first FDA-approved immunotherapy treatment—Bacillus Calmette-Guérin cancer vaccine—was for bladder cancer in 1990.

Brain Cancer

Cancers of the brain and nervous system are relatively rare but very serious. Immunotherapy is showing significant promise where other approaches have failed, including in glioblastoma.

Breast Cancer

New studies of immunotherapy in the treatment of breast cancer, one of the most commonly diagnosed cancer types among women globally, are encouraging, with the potential for long-term success.

Cervical Cancer

Three preventive cancer vaccines are already helping to stop cervical cancer, and many new immunotherapeutic approaches are in clinical trials.

Childhood Cancer

Immunotherapy offers a potential way to treat childhood (pediatric) cancer without the damaging, long-term side effects of conventional treatments.

Colorectal Cancer

There are several FDA-approved immunotherapies for colorectal cancer, for which patients are in urgent need of new treatment options.

Esophageal Cancer

Immunotherapy for esophageal cancer is being explored to reduce recurrence, as a first-line treatment, and in novel combinations for advanced stage cancer.

Head and Neck Cancer

Immunotherapy offers exciting new treatment options for patients with cancers of the mouth, throat, voice box, sinuses, nose, and salivary glands.

Kidney Cancer

Immunotherapy for kidney cancer—also called renal cell cancer—has tremendously changed the treatment landscape and overall survival of patients with metastatic kidney cancer. 

Leukemia

There are several FDA-approved immunotherapies for leukemia (leukaemia) and ongoing research demonstrates even greater potential for new treatments.

Liver Cancer

In addition to the first FDA-approved hepatitis B preventive cancer vaccine, immunotherapy treatments can enhance the immune system’s response to liver cancer.

Lung Cancer

Immunotherapy is a promising treatment option for advanced lung cancer, alone or in combination with conventional treatments like chemotherapy or surgery.

Lymphoma

Several FDA-approved immunotherapies offer treatment options to children and adults with Hodgkin and non-Hodgkin lymphoma.

Melanoma

Immunotherapy has changed the way melanoma is treated. In particular, checkpoint inhibitors are responsible for the increasing survival rate for patients with metastatic melanoma. 

Multiple Myeloma

Immunotherapy for multiple myeloma is a promising new treatment option, with the potential to result in long-term cancer remission similar to the results of bone marrow transplantation.

Ovarian Cancer

Research into immunotherapy for ovarian cancer is promising, especially since more treatment options for patients and oncologists are urgently needed.

Pancreatic Cancer

Pancreatic cancer has few treatment options, so pancreatic cancer immunotherapy research is vital to providing patients with new hope.

Prostate Cancer

With a cancer vaccine and checkpoint inhibitor already approved, immunotherapy research offers new hope to patients with advanced prostate cancer.

Sarcoma

Immunotherapy for sarcoma has some success cases, including the earliest known instances of spontaneous regression, although sarcoma cancer immunology is still largely unknown. 

Skin Cancer

Skin cancers are common, often diagnosed at an early stage, and among the first cancers to respond to immunotherapy.

Stomach Cancer

Immunotherapies, including checkpoint inhibitors and targeted antibodies, offer promising new treatment options for stomach (gastric) cancer patients.

Uterine (Endometrial) Cancer

Immunotherapy for uterine (endometrial) cancer is an emerging area of research and treatment, especially for patients with advanced cases.